(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2011 (12.05.2011)

PCT

(10) International Publication Number
WO 2011/057027 A2

(51) International Patent Classification:
*A61K 38/16* (2006.01) *C07K 16/00* (2006.01)
*C07K 14/00* (2006.01) *A61P 3/10* (2006.01)
*C07H 21/00* (2006.01) *A61P 9/00* (2006.01)

(21) International Application Number:
PCT/US2010/055526

(22) International Filing Date:
4 November 2010 (04.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12/612,548 4 November 2009 (04.11.2009) US
61/258,181 4 November 2009 (04.11.2009) US

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GENGO, Peter, J.** [US/US]; 2334 Kyanite Place, Carlsbad, CA 92009 (US). **SABBAH, Hani, N.** [US/US]; 1141 Meadowood, Waterford, MI 48327 (US). **SHANKLEY, Nigel, P.** [GB/US]; 449 Marview Lane, Solana Beach, CA 92075 (US).

(74) Agents: **JOHNSON, Philip, S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*


**Published**:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: METHOD FOR TREATING HEART FAILURE WITH STRESSCOPIN-LIKE PEPTIDES

FIG. 1




(57) Abstract: The present invention relates to novel methods of treating heart failure comprising administering an amount of stresscopin-like peptide to a subject in need thereof; and substantially maintaining the amount of said peptide present in the plasma of said subject at a concentration resulting in a therapeutic benefit without a substantial increase in the heart rate of said subject. The method involves the use of stresscopin-like peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists.

WO 2011/057027 A2